22 42

Cited 0 times in

항암화학요법에 의하여 골수억제가 수반된 진행암 환자에서 Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF,LBD-005)의 제3상 임상연구;rhGM-CSF의 백혈구 감소증에 대한 효과

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author라선영-
dc.contributor.author유내춘-
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.contributor.author라선영-
dc.contributor.author유내춘-
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.contributor.author라선영-
dc.contributor.author유내춘-
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.contributor.author라선영-
dc.contributor.author유내춘-
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.date.accessioned2021-12-27T17:02:21Z-
dc.date.available2021-12-27T17:02:21Z-
dc.date.issued1995-01-
dc.identifier.issn0496-6872-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186339-
dc.description.abstractBackground: Recombinant human granulocyte-macrophage colony stimulating factor(rhGM- CSF, LBD-005) may reduce chemotherapy induced myelosuppression, and thus reduce the incidence of neutropenic fever and infection after the dose intensive chemotherapy. In previous phase I and II studies, clinical efficacies and side effects of rhGM-CSF were evaluated, and the dose of 250ug/m(2)/day for 10 consecutive days subcutaneous administration was recommended for the further clinical triaL Methods: In this phase III trial, we evaluated the efficacy and safety of rhGM-CSF in 35 advanced cancer pstients after combination chemotherapy. Every eligible patients received at least 2 cycles of chemotherapy with the same dose and schedule. At the first cycle, control period, scheduled chemotherapy was given without rhGM-CSF, and at the second cycle, treatment period, rhGM-CSF was administered for 10 consecutive days subcutaneously with the dose of 250u/m(2)/day after the same chemotherapy given previously. During observation and treatment period, clinical and pathoiogical effects were monitered. Resnlta: All enrolled 35 patients were evaluable, and 14 patients(40%) had stomach cancer. The hematologic parameters were compared between two periods; mean nadir of WBC(neutrophil) counts during the control period and treatment period were 1,154+-485/mm(3)(241/mm(3)+ 242) and 2,486+1,554/mm(3)(912+-1,186/mm(3)) respectively(P<0.0001). Also the recovery time of neutropenia was shortened(P<0.0001). Incidence of infection and the necessities of antibiotics administration were decreased(days of antibiotics adminiatration: 7 days during control period and 10 days during treatment period). Most petients showed mild, talerable toxicities like chest tightness and general malaise, except 2 patients with the reduced dose of 150 ug/m(2)/day due to grade II toxicities of chest tightness and abdominal pain. Conclnsion: Above results suggested that the administration of rhGM-CSF after chemotherapy can reduce the degree of neutropenia and the side effects of rhGM-CSF were acceptable.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한암학회-
dc.relation.isPartOfJournal of the Korean Cancer Association(대한암학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title항암화학요법에 의하여 골수억제가 수반된 진행암 환자에서 Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF,LBD-005)의 제3상 임상연구;rhGM-CSF의 백혈구 감소증에 대한 효과-
dc.title.alternativeA Phase III Clinical Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF, LBD-005) in Cancer Patients with Chemotherapy-induced Myelosuppression-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthor이경희-
dc.contributor.googleauthor라선영-
dc.contributor.googleauthor노재경-
dc.contributor.googleauthor이종인-
dc.contributor.googleauthor이혜란-
dc.contributor.googleauthor박준오-
dc.contributor.googleauthor조재용-
dc.contributor.googleauthor정현철-
dc.contributor.googleauthor김주항-
dc.contributor.localIdA00945-
dc.contributor.localIdA01316-
dc.contributor.localIdA02457-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.contributor.localIdA01316-
dc.contributor.localIdA02457-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.contributor.localIdA01316-
dc.contributor.localIdA02457-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.contributor.localIdA01316-
dc.contributor.localIdA02457-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.relation.journalcodeJ01813-
dc.subject.keywordrhGM-CSF-
dc.subject.keywordCancer patients-
dc.subject.keywordCombinetion chemotherapy-
dc.subject.keywordMyelosuppression-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.affiliatedAuthor김주항-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor유내춘-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor조재용-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor유내춘-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor조재용-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor유내춘-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor조재용-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor유내춘-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor조재용-
dc.citation.volume27-
dc.citation.number5-
dc.citation.startPage804-
dc.citation.endPage815-
dc.identifier.bibliographicCitationJournal of the Korean Cancer Association (대한암학회지), Vol.27(5) : 804-815, 1995-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.